

Jack D Sobel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12057664/publications.pdf>

Version: 2024-02-01

276
papers

33,734
citations

9264

74
h-index

3830

178
g-index

288
all docs

288
docs citations

288
times ranked

20957
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. Clinical Infectious Diseases, 2022, 74, 2129-2135.	5.8	12
2	Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clinical Infectious Diseases, 2022, 74, 1979-1985.	5.8	38
3	Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 412-420.	2.3	27
4	Mixed Vaginitis Due to Bacterial Vaginosis and Candidiasis. Journal of Lower Genital Tract Disease, 2022, 26, 68-70.	1.9	9
5	Lower Genital Tract Microbiome—A Work in Progress. Journal of Lower Genital Tract Disease, 2022, 26, 71-72.	1.9	0
6	Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 2022, 74, S162-S168.	5.8	25
7	Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 2022, 74, S144-S151.	5.8	16
8	Ibrexafungerp for the treatment of vulvovaginal candidiasis. Drugs of Today, 2022, 58, 149-158.	1.1	1
9	The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment. Antibiotics, 2022, 11, 500.	3.7	14
10	Vulvovaginal candidiasis: An overview of mycological, clinical, and immunological aspects. Journal of Obstetrics and Gynaecology Research, 2022, 48, 1546-1560.	1.3	13
11	Antimicrobial Susceptibility of Microbiota in Bacterial Vaginosis Using Fluorescence In Situ Hybridization. Pathogens, 2022, 11, 456.	2.8	3
12	Donald Kaye: 1931–2020, in Memoriam. Clinical Infectious Diseases, 2021, 72, 2244-2245.	5.8	0
13	A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis. Clinical Infectious Diseases, 2021, 73, e1518-e1524.	5.8	39
14	Syndromic Treatment of Women With Vulvovaginal Symptoms in the United States: A Call to Action!. Clinical Infectious Diseases, 2021, 72, 1544-1545.	5.8	7
15	Cell wall protein variation, break-induced replication, and subtelomere dynamics in <i>Candida glabrata</i> . Molecular Microbiology, 2021, 116, 260-276.	2.5	16
16	Current and emerging pharmacotherapy for recurrent bacterial vaginosis. Expert Opinion on Pharmacotherapy, 2021, 22, 1593-1600.	1.8	11
17	Recurrent Bacterial Vaginosis: An Unmet Therapeutic Challenge. Experience With a Combination Pharmacotherapy Long-Term Suppressive Regimen. Sexually Transmitted Diseases, 2021, 48, 761-765.	1.7	14
18	Elevated COVID19 mortality risk in Detroit area hospitals among patients from census tracts with extreme socioeconomic vulnerability. EClinicalMedicine, 2021, 34, 100814.	7.1	9

#	ARTICLE	IF	CITATIONS
19	Vaginal Isolates of <i>Candida glabrata</i> Are Uniquely Susceptible to Ionophoric Killer Toxins Produced by <i>Saccharomyces cerevisiae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0245020.	3.2	4
20	<i>In Vitro</i> pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant <i>Candida</i> Isolates from Women with Vulvovaginal Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0056221.	3.2	11
21	Prognosis of recurrent bacterial vaginosis based on longitudinal changes in abundance of <i>Lactobacillus</i> and specific species of <i>Gardnerella</i> . <i>PLoS ONE</i> , 2021, 16, e0256445.	2.5	15
22	Protozoan-Viral-Bacterial Co-Infections Alter Galectin Levels and Associated Immunity Mediators in the Female Genital Tract. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 649940.	3.9	10
23	Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment. <i>BMC Medicine</i> , 2021, 19, 194.	5.5	38
24	Data on Safety of Intravaginal Boric Acid Use in Pregnant and Nonpregnant Women: A Narrative Review. <i>Sexually Transmitted Diseases</i> , 2021, 48, e241-e247.	1.7	5
25	Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e672-e679.	5.8	18
26	Algorithm for Managing Vulvovaginal Symptoms. , 2021, , 544-551.		0
27	Non-infectious Benign Vaginal Conditions. , 2021, , 257-265.		0
28	Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis. <i>Future Microbiology</i> , 2021, 16, 1453-1461.	2.0	42
29	Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by <i>Candida albicans</i> . <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 48-52.	1.9	28
30	Desquamative Inflammatory Vaginitis as an Extraintestinal Manifestation of Crohn's Disease. <i>Current Infectious Disease Reports</i> , 2020, 22, 1.	3.0	0
31	Diversity of the hepatitis C virus NS5B gene during HIV co-infection. <i>PLoS ONE</i> , 2020, 15, e0237162.	2.5	5
32	Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 893-900.	4.1	38
33	Use of a Novel Couples' Verification Tool in a Male Partner Treatment Study of Women With Recurrent Bacterial Vaginosis. <i>Sexually Transmitted Diseases</i> , 2020, 47, e58-e61.	1.7	4
34	Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 2297-2307.	2.7	16
35	Algorithms for Managing Vulvovaginal Symptoms—a Practical Primer. <i>Current Infectious Disease Reports</i> , 2019, 21, 40.	3.0	5
36	Prognostic Indicators of Recurrence of Bacterial Vaginosis. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	29

#	ARTICLE	IF	CITATIONS
37	Re: A systematic review of drug treatment of vulvodynia: evidence of a strong placebo effect. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 945-946.	2.3	1
38	Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Women's Health, 2019, 19, 48.	2.0	133
39	CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. Journal of Lower Genital Tract Disease, 2019, 23, 226-229.	1.9	16
40	A Role for Yeast/Pseudohyphal Cells of Candida albicans in the Correlated Expression of NLRP3 Inflammasome Inducers in Women With Acute Vulvovaginal Candidiasis. Frontiers in Microbiology, 2019, 10, 2669.	3.5	14
41	Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. American Journal of Obstetrics and Gynecology, 2019, 220, 91.e1-91.e8.	1.3	67
42	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. Clinical Infectious Diseases, 2019, 68, 1981-1989.	5.8	120
43	A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2018, 66, 1928-1936.	5.8	134
44	A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered AVT-1161 in the treatment of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 2018, 218, 624.e1-624.e9.	1.3	68
45	Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. Journal of Lower Genital Tract Disease, 2018, 22, 382-386.	1.9	16
46	Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infectious Diseases, The, 2018, 18, e339-e347.	9.1	334
47	Good Clinical Practice in Diagnosis of Vulvovaginal Symptoms. JAMA Internal Medicine, 2018, 178, 1135.	5.1	0
48	Reply. American Journal of Obstetrics and Gynecology, 2017, 216, 427.	1.3	0
49	Cytokine/chemokine expression associated with Human Pegivirus (HPgV) infection in women with HIV. Journal of Medical Virology, 2017, 89, 1904-1911.	5.0	12
50	The Role of Resistance in Candida Infections: Epidemiology and Treatment. , 2017, , 1075-1097.		4
51	Vaginitis, Vulvitis, Cervicitis and Cutaneous Vulval Lesions. , 2017, , 483-491.e1.		6
52	Candida vulvovaginitis: A store with a butterfly and a show window. Mycoses, 2017, 60, 70-72.	4.0	23
53	In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis. Journal of Antimicrobial Chemotherapy, 2017, 72, 1355-1358.	3.0	28
54	Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans. , 2017, , 429-475.		3

#	ARTICLE	IF	CITATIONS
55	Bacterial Vaginosis. , 2017, , 165-174.		2
56	Current Treatment of Bacterial Vaginosis—Limitations and Need for Innovation. Journal of Infectious Diseases, 2016, 214, S14-S20.	4.0	156
57	A Combination Fluorescence Assay Demonstrates Increased Efflux Pump Activity as a Resistance Mechanism in Azole-Resistant Vaginal Candida albicans Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 5858-5866.	3.2	64
58	Utilization of molecular methods to identify prognostic markers for recurrent bacterial vaginosis. Diagnostic Microbiology and Infectious Disease, 2016, 86, 231-242.	1.8	25
59	Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nature Communications, 2016, 7, 11128.	12.8	227
60	Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clinical Infectious Diseases, 2016, 63, 754-762.	5.8	281
61	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, 409-417.	5.8	1,258
62	Development and Validation of a Highly Accurate Quantitative Real-Time PCR Assay for Diagnosis of Bacterial Vaginosis. Journal of Clinical Microbiology, 2016, 54, 1017-1024.	3.9	74
63	Experimental Models of Vaginal Candidiasis and Their Relevance to Human Candidiasis. Infection and Immunity, 2016, 84, 1255-1261.	2.2	42
64	Fungal Infections. Infectious Disease Clinics of North America, 2016, 30, xiii-xiv.	5.1	3
65	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 62, e1-e50.	5.8	2,489
66	Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis. Diagnostic Microbiology and Infectious Disease, 2016, 84, 1-3.	1.8	57
67	Recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 2016, 214, 15-21.	1.3	373
68	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. Sexually Transmitted Diseases, 2015, 42, 376-381.	1.7	22
69	Editorial Commentary: Vaginal Biofilm: Much Ado About Nothing, or a New Therapeutic Challenge?. Clinical Infectious Diseases, 2015, 61, 607-608.	5.8	25
70	CX ₃ CR1 Is Dispensable for Control of Mucosal Candida albicans Infections in Mice and Humans. Infection and Immunity, 2015, 83, 958-965.	2.2	31
71	Metronidazole for the treatment of vaginal infections. Expert Opinion on Pharmacotherapy, 2015, 16, 1109-1115.	1.8	52
72	A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections. Clinical Infectious Diseases, 2015, 61, S837-S848.	5.8	121

#	ARTICLE	IF	CITATIONS
73	Dense Genotyping of Immune-Related Loci Identifies Variants Associated with Clearance of HPV among HIV-Positive Women in the HIV Epidemiology Research Study (HERS). PLoS ONE, 2014, 9, e99109.	2.5	14
74	GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV) Seropositive Women with or at Risk for HIV Infection. PLoS ONE, 2014, 9, e114467.	2.5	8
75	Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Current Medical Research and Opinion, 2014, 30, 1109-1119.	1.9	124
76	Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Frontiers in Microbiology, 2014, 5, 483.	3.5	66
77	1411Utilization of PCR to Characterize Vaginal Flora in a Longitudinal Study of Recurrent Bacterial Vaginosis. Open Forum Infectious Diseases, 2014, 1, S371-S372.	0.9	0
78	High-Dose Vaginal Maintenance Metronidazole for Recurrent Bacterial Vaginosis. Sexually Transmitted Diseases, 2014, 41, 290-291.	1.7	20
79	High-Dose Vaginal Metronidazole for Recurrent Bacterial Vaginosisâ€”A Pilot Study. Journal of Lower Genital Tract Disease, 2014, 18, 156-161.	1.9	11
80	MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting. Clinical Infectious Diseases, 2014, 58, 1219-1226.	5.8	142
81	Multiplex quantitative polymerase chain reaction assay for the identification and quantitation of major vaginal lactobacilli. Diagnostic Microbiology and Infectious Disease, 2014, 78, 321-327.	1.8	29
82	Genital candidiasis. Medicine, 2014, 42, 364-368.	0.4	17
83	Are Echinocandins Better Than Azoles for Invasive Candidiasis?. Current Fungal Infection Reports, 2013, 7, 79-82.	2.6	2
84	Mixed Vaginitisâ€”More Than Coinfection and With Therapeutic Implications. Current Infectious Disease Reports, 2013, 15, 104-108.	3.0	77
85	Genital Mycotic Infections in Patients With Diabetes. Postgraduate Medicine, 2013, 125, 33-46.	2.0	70
86	Novel PCR-Based Methods Enhance Characterization of Vaginal Microbiota in a Bacterial Vaginosis Patient before and after Treatment. Applied and Environmental Microbiology, 2013, 79, 4181-4185.	3.1	20
87	Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States. Journal of Lower Genital Tract Disease, 2013, 17, 340-345.	1.9	201
88	Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Patient Preference and Adherence, 2013, 8, 31.	1.8	31
89	Longitudinal Analysis of Vaginal Microbiome Dynamics in Women with Recurrent Bacterial Vaginosis: Recognition of the Conversion Process. PLoS ONE, 2013, 8, e82599.	2.5	53
90	Genital Malodor in Women. Journal of Lower Genital Tract Disease, 2012, 16, 49-55.	1.9	6

#	ARTICLE	IF	CITATIONS
91	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2012, 54, 1110-1122.	5.8	649
92	Effect of pH on <i>In Vitro</i> Susceptibility of <i>Candida glabrata</i> and <i>Candida albicans</i> to 11 Antifungal Agents and Implications for Clinical Use. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1403-1406.	3.2	91
93	Fluconazole-Resistant <i>Candida albicans</i> Vulvovaginitis. <i>Obstetrics and Gynecology</i> , 2012, 120, 1407-1414.	2.4	151
94	Miconazole Mucoadhesive Tablets: A Novel Delivery System. <i>Clinical Infectious Diseases</i> , 2012, 54, 1480-1484.	5.8	31
95	Diagnosing vaginal infections through measurement of biogenic amines by ion mobility spectrometry. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 163, 81-84.	1.1	31
96	A case of <i>Conidiobolus coronatus</i> in the vagina. <i>Medical Mycology</i> , 2011, 49, 427-429.	0.7	7
97	<i>Candida</i> Urinary Tract Infections—Diagnosis. <i>Clinical Infectious Diseases</i> , 2011, 52, S452-S456.	5.8	123
98	<i>Candida glabrata</i> complicating in vitro pregnancy: successful management of subsequent pregnancy. <i>Fertility and Sterility</i> , 2011, 95, 803.e1-803.e2.	1.0	18
99	Douching for Perceived Vaginal Odor With No Infectious Cause of Vaginitis. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 128-133.	1.9	5
100	Prognosis and Treatment of Desquamative Inflammatory Vaginitis. <i>Obstetrics and Gynecology</i> , 2011, 117, 850-855.	2.4	60
101	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. <i>Mycoses</i> , 2011, 54, 46-51.	4.0	98
102	Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 177-190.	1.3	152
103	A Case of High-Level Metronidazole-Resistant Trichomoniasis in Pregnancy Successfully Treated. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 248-249.	1.9	4
104	The Association Between Trichomonas Infection and Incarceration in HIV-Seropositive and At-Risk HIV-Seronegative Women. <i>Sexually Transmitted Diseases</i> , 2011, 38, 1094-1100.	1.7	20
105	<i>Candida</i> Urinary Tract Infection: Pathogenesis. <i>Clinical Infectious Diseases</i> , 2011, 52, S437-S451.	5.8	113
106	<i>Candida</i> Urinary Tract Infections—Epidemiology. <i>Clinical Infectious Diseases</i> , 2011, 52, S433-S436.	5.8	178
107	<i>Candida</i> Urinary Tract Infections—Treatment. <i>Clinical Infectious Diseases</i> , 2011, 52, S457-S466.	5.8	157
108	Ocular Manifestations of Candidemia. <i>Clinical Infectious Diseases</i> , 2011, 53, 262-268.	5.8	171

#	ARTICLE	IF	CITATIONS
109	Association between Semen Exposure and Incident Bacterial Vaginosis. Infectious Diseases in Obstetrics and Gynecology, 2011, 2011, 1-10.	1.5	28
110	Accuracy of Clinical Diagnosis of Bacterial Vaginosis by Human Immunodeficiency Virus Infection Status. Sexually Transmitted Diseases, 2011, 38, 270-274.	1.7	12
111	Septic Shock Due to Candidemia: Outcomes and Predictors of Shock Development. Journal of Clinical Medicine Research, 2011, 3, 65-71.	1.2	32
112	Genital Candidiasis. , 2011, , 613-624.		1
113	Candida kefyr Endocarditis in a Patient With Hypertrophic Obstructive Cardiomyopathy. American Journal of the Medical Sciences, 2010, 339, 188-189.	1.1	13
114	Dynamics of the Vaginal Ecosystemâ€™ Hormonal Influences. Infectious Diseases: Research and Treatment, 2010, 3, IDRT.S3903.	1.7	37
115	Yeast Infections of the Lower Urinary Tract: Recommendations for Diagnosis and Treatment. Current Fungal Infection Reports, 2010, 4, 175-178.	2.6	3
116	Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights. Current Infectious Disease Reports, 2010, 12, 465-470.	3.0	94
117	Genital candidiasis. Medicine, 2010, 38, 286-290.	0.4	7
118	Chronic Pain of the Vulva without Dermatologic Manifestations: Distinguishing among a Spectrum of clinical Disorders. Clinical Medicine Insights Women's Health, 2010, 3, CMWH.S3950.	0.6	2
119	Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDSâ€™Associated Acute Cryptococcal Meningitis: A Randomized, Doubleâ€™Blind Clinical Trial of Efficacy and Safety. Clinical Infectious Diseases, 2010, 51, 225-232.	5.8	150
120	Diagnostic techniques for bacterial vaginosis and vulvovaginal candidiasis â€™ requirement for a simple differential test. Expert Opinion on Medical Diagnostics, 2010, 4, 333-341.	1.6	8
121	Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2010, 50, 291-322.	5.8	2,195
122	Vaginitis, vulvitis, cervicitis and cutaneous vulval lesions. , 2010, , 542-550.		1
123	The Vaginal Microbiota in Menopause. , 2010, , 883-893.		2
124	Guidelines for the treatment of bacterial vaginosis: focus on tinidazole. Therapeutics and Clinical Risk Management, 2009, 5, 485.	2.0	21
125	Fungal infections of the genitourinary tract. , 2009, , 547-559.		1
126	A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIVâ€™Associated Cryptococcal Meningitis. Clinical Infectious Diseases, 2009, 48, 1775-1783.	5.8	141

127	Use of the VS-Sense Swab in Diagnosing Vulvovaginitis. Journal of Women's Health, 2009, 18, 1467-1470.	3.3	6
128	Boric Acid Addition to Suppressive Antimicrobial Therapy for Recurrent Bacterial Vaginosis. Sexually Transmitted Diseases, 2009, 36, 732-734.	1.7	87
129	Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study. Clinical Infectious Diseases, 2009, 49, 931-934.	5.8	103
130	Antibiotic consideration in bacterial vaginosis. Current Infectious Disease Reports, 2009, 11, 471-475.	3.0	13
131	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 503-535.	5.8	2,644
132	Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagnostic Microbiology and Infectious Disease, 2009, 64, 354-356.	1.8	48
133	Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans. , 2009, , 347-407.		5
134	Fungal endocarditis. Current Infectious Disease Reports, 2008, 10, 275-279.	3.0	15
135	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	5.8	4,375
136	Effect of Antibiotics on Vulvovaginal Candidiasis: A MetroNet Study. Journal of the American Board of Family Medicine, 2008, 21, 261-268.	1.5	76
137	Empirical Fluconazole versus Placebo for Intensive Care Unit Patients. Annals of Internal Medicine, 2008, 149, 83.	3.9	191
138			

#	ARTICLE	IF	CITATIONS
145	Bacterial vaginosis: Culture- and PCR-based characterizations of a complex polymicrobial diseaseâ€™s pathobiology. Current Infectious Disease Reports, 2007, 9, 485-500.	3.0	34
146	The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Current Fungal Infection Reports, 2007, 1, 42-48.	2.6	6
147	Failure of Nitazoxanide to Cure Trichomoniasis in Three Women. Sexually Transmitted Diseases, 2007, 34, 813-814.	1.7	20
148	Progress in antifungal therapy: Echinocandins versus azoles. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 221-226.	0.5	1
149	Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. American Journal of Obstetrics and Gynecology, 2006, 194, 1283-1289.	1.3	249
150	The VI-SENSEâ€™vaginal discharge self-test to facilitate management of vaginal symptoms. American Journal of Obstetrics and Gynecology, 2006, 195, 1351-1356.	1.3	18
151	The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Current Infectious Disease Reports, 2006, 8, 427-433.	3.0	78
152	Management of recurrent vulvovaginal candidiasis: Unresolved issues. Current Infectious Disease Reports, 2006, 8, 481-486.	3.0	27
153	Design of Clinical Trials of Empiric Antifungal Therapy in Patients with Persistent Febrile Neutropenia: Considerations and Critiques. Pharmacotherapy, 2006, 26, 47S-54S.	2.6	7
154	Antifungal Bladder Irrigation. Infectious Diseases in Clinical Practice, 2006, 14, 125-126.	0.3	4
155	Reviews Of Antiâ€™infective Agents: Anidulafungin: A Novel Echinocandin. Clinical Infectious Diseases, 2006, 43, 215-222.	5.8	176
156	advances in diagnosing vaginitis: Development of a new algorithm. Current Infectious Disease Reports, 2005, 7, 458-462.	3.0	18
157	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clinical Infectious Diseases, 2005, 41, 1473-1480.	5.8	72
158	Genital candidiasis. Medicine, 2005, 33, 62-65.	0.4	13
159	What's New in Bacterial Vaginosis and Trichomoniasis?. Infectious Disease Clinics of North America, 2005, 19, 387-406.	5.1	93
160	Emerging azole antifungals. Expert Opinion on Emerging Drugs, 2005, 10, 21-33.	2.4	50
161	Combination Therapy for Invasive Mycoses: Evaluation of Past Clinical Trial Designs. Clinical Infectious Diseases, 2004, 39, S224-S227.	5.8	19
162	Fungicidal Activity of Fluconazole against Candida albicans in a Synthetic Vagina-Simulative Medium. Antimicrobial Agents and Chemotherapy, 2004, 48, 161-167.	3.2	57

#	ARTICLE	IF	CITATIONS
163	Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study. American Journal of Obstetrics and Gynecology, 2004, 190, 644-653.	1.3	77
164	Shuttle vectors for Candida albicans : control of plasmid copy number and elevated expression of cloned genes. Current Genetics, 2004, 45, 390-398.	1.7	23
165	Candida vulvovaginitis in pregnancy. Current Infectious Disease Reports, 2004, 6, 445-449.	3.0	16
166	Guidelines for Treatment of Candidiasis. Clinical Infectious Diseases, 2004, 38, 161-189.	5.8	1,371
167	Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis. New England Journal of Medicine, 2004, 351, 876-883.	27.0	408
168	Fluconazole for the treatment of candidiasis: 15 years experience. Expert Review of Anti-Infective Therapy, 2004, 2, 357-366.	4.4	71
169	Current trends and challenges in candidiasis. Oncology, 2004, 18, 7-8.	0.5	1
170	Estrogen replacement therapy to prevent recurrent urinary tract infection in postmenopausal women. Current Infectious Disease Reports, 2003, 5, 479-480.	3.0	2
171	Antibiotic-associated vulvovaginal candidiasis. Current Infectious Disease Reports, 2003, 5, 481-487.	3.0	18
172	Erosive vulvovaginitis. Current Infectious Disease Reports, 2003, 5, 494-498.	3.0	2
173	Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. American Journal of Obstetrics and Gynecology, 2003, 189, 1297-1300.	1.3	160
174	Vulvovaginal candidiasis. Obstetrics and Gynecology Clinics of North America, 2003, 30, 671-684.	1.9	39
175	Management of Patients with Recurrent Vulvovaginal Candidiasis. Drugs, 2003, 63, 1059-1066.	10.9	60
176	CAN-296-P is effective against cutaneous candidiasis in guinea pigs. International Journal of Antimicrobial Agents, 2003, 22, 168-171.	2.5	6
177	Longitudinal Study of Mucosal Candida Species Colonization and Candidiasis among Human Immunodeficiency Virus (HIV)â€“Seropositive and Atâ€“Risk HIVâ€“Seronegative Women. Journal of Infectious Diseases, 2003, 188, 118-127.	4.0	83
178	Antifungal drugs in pregnancy: a review. Expert Opinion on Drug Safety, 2003, 2, 475-483.	2.4	80
179	Incident and persistent vulvovaginal candidiasis among human immunodeficiency virusâ€“infected women: Risk factors and severity. Obstetrics and Gynecology, 2003, 101, 548-556.	2.4	46
180	Incident and Persistent Vulvovaginal Candidiasis Among Human Immunodeficiency Virusâ€“Infected Women. Obstetrics and Gynecology, 2003, 101, 548-556.	2.4	31

#	ARTICLE	IF	CITATIONS
181	Vulvovaginal Trichosporonosis. Infectious Diseases in Obstetrics and Gynecology, 2003, 11, 131-133.	1.5	9
182	Vulvovaginal candidiasis: a comparison of HIV-positive and -negative women. International Journal of STD and AIDS, 2002, 13, 358-362.	1.1	28
183	Uropathogenic Escherichia coli Are More Likely than Commensal E. coli to Be Shared between Heterosexual Sex Partners. American Journal of Epidemiology, 2002, 156, 1133-1140.	3.4	96
184	Over-the-Counter Antifungal Drug Misuse Associated With Patient-Diagnosed Vulvovaginal Candidiasis. Obstetrics and Gynecology, 2002, 99, 419-425.	2.4	7
185	Vaginitis Due to Candida krusei: Epidemiology, Clinical Aspects, and Therapy. Clinical Infectious Diseases, 2002, 35, 1066-1070.	5.8	91
186	Treatment of vaginal Candida infections. Expert Opinion on Pharmacotherapy, 2002, 3, 1059-1065.	1.8	43
187	Oral and vaginal antifungal treatments are similarly effective for vulvovaginal candidiasis â€“ meta-analysis. Evidence-Based Obstetrics and Gynecology, 2002, 4, 158-159.	0.0	0
188	Desquamative Inflammatory Vaginitis An Exploratory Case-Control Study. Annals of Epidemiology, 2002, 12, 346-352.	1.9	27
189	Mucosal candidiasis. Infectious Disease Clinics of North America, 2002, 16, 793-820.	5.1	93
190	Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstetrics and Gynecology, 2002, 99, 419-425.	2.4	160
191	Steroid therapy of vulvovaginal lichen planus. Current Infectious Disease Reports, 2002, 4, 507-508.	3.0	6
192	Pathogenesis of recurrent vulvovaginal candidiasis. Current Infectious Disease Reports, 2002, 4, 514-519.	3.0	49
193	Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infectious Diseases, 2002, 2, 1.	2.9	174
194	Urinary tract infection among women aged 40 to 65. Journal of Clinical Epidemiology, 2001, 54, 710-718.	5.0	74
195	Evolution of Antifungal Susceptibility among Candida Species Isolates Recovered from Human Immunodeficiency Virusâ€“Infected Women Receiving Fluconazole Prophylaxis. Clinical Infectious Diseases, 2001, 33, 1069-1075.	5.8	54
196	Vaginal Mucormycosis: A Case Report. Infectious Diseases in Obstetrics and Gynecology, 2001, 9, 117-118.	1.5	14
197	Alternative treatment modalities for prevention of urinary tract infection in women: Lactobacilli or cranberry juice?. Current Infectious Disease Reports, 2001, 3, 527-528.	3.0	0
198	Antimicrobial resistance in vulvovaginitis. Current Infectious Disease Reports, 2001, 3, 546-549.	3.0	5

#	ARTICLE	IF	CITATIONS
199	<i>Candida glabrata</i> : an important fungal pathogen for the 21st century. Clinical Microbiology Newsletter, 2001, 23, 171-176.	0.7	3
200	Prophylactic Antifungal Therapy in the Intensive Care Unit. Clinical Infectious Diseases, 2001, 32, 1191-1200.	5.8	168
201	The Evolution of <i>Candida</i> Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)-Seropositive and At-Risk HIV-Seronegative Women. Journal of Infectious Diseases, 2001, 183, 286-293.	4.0	75
202	Genital Candidosis. Medicine, 2001, 29, 67-73.	0.4	0
203	Nontrichomonal purulent vaginitis: Clinical approach. Current Infectious Disease Reports, 2000, 2, 501-505.	3.0	11
204	Management of infections caused by <i>Candida glabrata</i> . Current Infectious Disease Reports, 2000, 2, 424-428.	3.0	12
205	<i>Candida</i> vaginitis. Sexually Transmitted Diseases, 2000, 27, 230-235.	1.7	133
206	Practice Guidelines for the Treatment of Fungal Infections. Clinical Infectious Diseases, 2000, 30, 652-652.	5.8	70
207	Urinary Tract Infection. Annals of Epidemiology, 2000, 10, 509-515.	1.9	828
208	Gynecologic Infections in Human Immunodeficiency Virus-Infected Women. Clinical Infectious Diseases, 2000, 31, 1225-1233.	5.8	61
209	Use of Antifungal Drugs in Pregnancy. Drug Safety, 2000, 23, 77-85.	3.2	48
210	Bacterial Vaginosis. Annual Review of Medicine, 2000, 51, 349-356.	12.2	251
211	<i>Candida glabrata</i> : Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to <i>C. albicans</i> . Clinical Microbiology Reviews, 1999, 12, 80-96.	13.6	819
212	High-Frequency, In Vitro Reversible Switching of <i>Candida lusitanae</i> Clinical Isolates from Amphotericin B Susceptibility to Resistance. Antimicrobial Agents and Chemotherapy, 1999, 43, 836-845.	3.2	81
213	Involvement of calcium inhibitable binding to the cell wall in the fungicidal activity of CAN-296. Journal of Antimicrobial Chemotherapy, 1999, 44, 217-222.	3.0	7
214	Mass or syndromic treatment of sexually transmitted infections. Current Infectious Disease Reports, 1999, 1, 365-366.	3.0	0
215	Is there a protective role for vaginal flora?. Current Infectious Disease Reports, 1999, 1, 379-383.	3.0	82
216	Metronidazole-Resistant Vaginal Trichomoniasis – An Emerging Problem. New England Journal of Medicine, 1999, 341, 292-293.	27.0	97

#	ARTICLE	IF	CITATIONS
217	Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges. Drug Resistance Updates, 1999, 2, 148-152.	14.4	13
218	Comparative in Vitro Activity of Antiseptics and Disinfectants Versus Clinical Isolates of Candida Species. Infection Control and Hospital Epidemiology, 1999, 20, 676-684.	1.8	18
219	Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. American Journal of Obstetrics and Gynecology, 1998, 178, 203-211.	1.3	540
220	Frequency and Response to Vaginal Symptoms among White and African American Women: Results of a Random Digit Dialing Survey. Journal of Women's Health, 1998, 7, 1167-1174.	0.9	75
221	VULVOVAGINITIS. Dermatologic Clinics, 1998, 16, 763-768.	1.7	22
222	Mucosal Candidal Colonization and Candidiasis in Women with or at Risk for Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 1998, 27, 1161-1167.	5.8	92
223	Difficult to Treat Trichomoniasis: Results with Paromomycin Cream. Clinical Infectious Diseases, 1998, 26, 986-988.	5.8	69
224	Nosocomial <i>Candida glabrata</i> Colonization: an Epidemiologic Study. Journal of Clinical Microbiology, 1998, 36, 421-426.	3.9	112
225	Stable Phenotypic Resistance of <i>Candida</i> Species to Amphotericin B Conferred by Preexposure to Subinhibitory Levels of Azoles. Journal of Clinical Microbiology, 1998, 36, 2690-2695.	3.9	39
226	Development and verification of fingerprinting probes for Candida glabrata. Microbiology (United Kingdom), 1998, 142, 1071-1076.	1.8	70
227	Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine, 1997, 337, 15-21.	27.0	745
228	In Vitro Antifungal Activity of CAN-296: A Naturally Occurring Complex Carbohydrate.. Journal of Antibiotics, 1997, 50, 937-943.	2.0	7
229	Vaginitis. New England Journal of Medicine, 1997, 337, 1896-1903.	27.0	450
230	PATHOGENESIS OF URINARY TRACT INFECTION. Infectious Disease Clinics of North America, 1997, 11, 531-549.	5.1	85
231	Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women. Obstetrics and Gynecology, 1996, 88, 704-706.	2.4	20
232	Validity of the Vaginal Gram Stain for the Diagnosis of Bacterial Vaginosis. Obstetrics and Gynecology, 1996, 88, 573-576.	2.4	212
233	Aphthous vaginal ulceration in two women with acquired immunodeficiency syndrome. American Journal of Obstetrics and Gynecology, 1996, 174, 1660-1663.	1.3	14
234	Comparative study of intravaginal metronidazole and triple-sulfa therapy for bacterial vaginosis. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 66-70.	1.5	4

#	ARTICLE	IF	CITATIONS
235	Trichomoniasis as seen in a chronic vaginitis clinic. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 77-84.	1.5	4
236	Candida vulvovaginitis. Seminars in Dermatology, 1996, 15, 17-28.	0.6	16
237	Comparative Study of Intravaginal Metronidazole and Triple-Sulfa Therapy for Bacterial Vaginosis. Infectious Diseases in Obstetrics and Gynecology, 1996, 4, 66-70.	1.5	1
238	Treatment Options for Vulvovaginal Candidiasis, 1993. Clinical Infectious Diseases, 1995, 20, S80-S90.	5.8	55
239	vaginitis: Transmission from yeast used in baking. Obstetrics and Gynecology, 1995, 86, 326-329.	2.4	37
240	Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. American Journal of Obstetrics and Gynecology, 1995, 172, 1263-1268.	1.3	135
241	FUNGAL INFECTIONS IN DIABETES. Infectious Disease Clinics of North America, 1995, 9, 97-116.	5.1	58
242	Candida Vaginitis. Infectious Diseases in Clinical Practice, 1994, 3, 334-339.	0.3	5
243	Controversial aspects in the management of vulvovaginal candidiasis. Journal of the American Academy of Dermatology, 1994, 31, S10-S13.	1.2	23
244	Desquamative inflammatory vaginitis: A new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. American Journal of Obstetrics and Gynecology, 1994, 171, 1215-1220.	1.3	129
245	The role of cell-mediated immunity in candidiasis. Trends in Microbiology, 1994, 2, 202-206.	7.7	102
246	Management of Vaginosis. Drug Investigation, 1994, 8, 26-34.	0.6	2
247	Nosocomial acquisition of Candida parapsilosis: An epidemiologic study. American Journal of Medicine, 1993, 94, 577-582.	1.5	124
248	Nosocomial Acquisition of Candida albicans: An Epidemiologic Study. Journal of Infectious Diseases, 1993, 168, 195-201.	4.0	165
249	Candidal Vulvovaginitis. Clinical Obstetrics and Gynecology, 1993, 36, 153-165.	1.1	143
250	Women and AIDS. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1993, 33, 341-350.	1.0	8
251	Vulvovaginitis. Dermatologic Clinics, 1992, 10, 339-359.	1.7	27
252	Urinary Excretion of Tamm-Horsfall Protein in Elderly Women. Journal of Urology, 1991, 146, 806-808.	0.4	21

#	ARTICLE	IF	CITATIONS
253	A New Slide Latex Agglutination Test for the Diagnosis of Acute Candida Vaginitis. American Journal of Clinical Pathology, 1990, 94, 323-325.	0.7	10
254	Vulvovaginal Candidiasis Complicating Recurrent Bacterial Vaginosis. Sexually Transmitted Diseases, 1990, 17, 51-53.	1.7	29
255	Emerging Role of Lactobacilli in the Control and Maintenance of the Vaginal Bacterial Microflora. Clinical Infectious Diseases, 1990, 12, 856-872.	5.8	448
256	Individualizing treatment of vaginal candidiasis. Journal of the American Academy of Dermatology, 1990, 23, 572-576.	1.2	12
257	Therapeutic Considerations in Fungal Vaginitis. Handbook of Experimental Pharmacology, 1990, , 365-383.	1.8	3
258	Vaginitis in Adult Women. Obstetrics and Gynecology Clinics of North America, 1990, 17, 851-879.	1.9	16
259	Bacterial Vaginosis-An Ecologic Mystery. Annals of Internal Medicine, 1989, 111, 551.	3.9	40
260	A New ELISA Method for the Rapid Quantification of Tamm-Horsfall Protein in Urine. American Journal of Clinical Pathology, 1989, 92, 199-205.	0.7	16
261	Pathogenesis of Candida Vulvovaginitis. Current Topics in Medical Mycology, 1989, 3, 86-108.	0.8	34
262	Pathogenesis and Epidemiology of Vulvovaginal Candidiasis. Annals of the New York Academy of Sciences, 1988, 544, 547-557.	3.8	179
263	Pathogenesis of Urinary Tract Infections Host Defenses. Infectious Disease Clinics of North America, 1987, 1, 751-772.	5.1	32
264	Zinc status in women with recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 1986, 155, 1082-1085.	1.3	23
265	Recurrent Vulvovaginal Candidiasis. New England Journal of Medicine, 1986, 315, 1455-1458.	27.0	202
266	Recurrent Vulvovaginal Candidiasis. Obstetrics and Gynecology, 1986, 67, 810-812.	2.4	23
267	Experimental chronic vaginal candidosis in rats. Medical Mycology, 1985, 23, 199-206.	0.7	65
268	Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. American Journal of Obstetrics and Gynecology, 1985, 152, 924-935.	1.3	300
269	Pathogenesis of Bacteriuria in Elderly Women: The Role of Escherichia Coli Adherence to Vaginal Epithelial Cells. Journal of Gerontology, 1984, 39, 682-685.	1.9	20
270	Vulvovaginal Candidiasis—What We Do and Do Not Know. Annals of Internal Medicine, 1984, 101, 390.	3.9	46

#	ARTICLE	IF	CITATIONS
271	Candiduria. , 0, , 457-460.		0
272	Non- <i>albicans Candida</i> Infections. , 0, , 393-411.		0
273	Candiduria. , 0, , 430-433.		0
274	Mucosal Candidiasis. , 0, , 417-427.		4
275	Determining Susceptibility in <i>Candida</i> Vaginal Isolates. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	4
276	Desquamative Inflammatory Vaginitis as an Expression of Systemic Lupus Erythematosus. Journal of Lower Genital Tract Disease, 0, Publish Ahead of Print, .	1.9	0